zaleplon has been researched along with flumazenil in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (57.14) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Bagal, SK; Brown, AD; Cox, PJ; Omoto, K; Owen, RM; Pryde, DC; Sidders, B; Skerratt, SE; Stevens, EB; Storer, RI; Swain, NA | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Choi, Y; Raymer, BK | 1 |
| Bergman, J; Cook, JM; Cox, ED; Paronis, CA | 1 |
| Carter, L; Cook, JM; France, CP; Gerak, LR; Ma, C; McMahon, LR | 1 |
| Höjer, J; Salmonson, H; Sundin, P | 1 |
| Haga, C | 1 |
| Foster, AC; Grigoriadis, DE; Gross, RS; Petroski, RE; Sullivan, SK; Verge, G | 1 |
| Biggio, F; Caria, S; Follesa, P; Gorini, G; Murru, L; Sanna, E | 1 |
| Gunja, N | 1 |
4 review(s) available for zaleplon and flumazenil
| Article | Year |
|---|---|
Ion channels as therapeutic targets: a drug discovery perspective.
Topics: Drug Discovery; Humans; Ion Channels; Models, Molecular; Phylogeny | 2013 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Sleep modulating agents.
Topics: Animals; Humans; Sleep; Sleep Aids, Pharmaceutical; Sleep Wake Disorders; Wakefulness-Promoting Agents | 2019 |
The clinical and forensic toxicology of Z-drugs.
Topics: Acetamides; Azabicyclo Compounds; Coma; Drug Overdose; Flumazenil; GABA Modulators; GABA-A Receptor Agonists; Humans; Hypnotics and Sedatives; Piperazines; Pyridines; Pyrimidines; Zolpidem | 2013 |
10 other study(ies) available for zaleplon and flumazenil
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Different types of GABA(A) receptors may mediate the anticonflict and response rate-decreasing effects of zaleplon, zolpidem, and midazolam in squirrel monkeys.
Topics: Acetamides; Animals; Carbolines; Dose-Response Relationship, Drug; Flumazenil; GABA Antagonists; GABA Modulators; GABA-A Receptor Agonists; Hypnotics and Sedatives; Male; Midazolam; Pyridines; Pyrimidines; Reaction Time; Receptors, GABA-A; Saimiri; Zolpidem | 2001 |
Discriminative stimulus effects of benzodiazepine (BZ)(1) receptor-selective ligands in rhesus monkeys.
Topics: Acetamides; Animals; Carbolines; Diazepam; Discrimination, Psychological; Dose-Response Relationship, Drug; Female; Flumazenil; GABA Agonists; GABA Antagonists; GABA Modulators; GABA-A Receptor Agonists; GABA-A Receptor Antagonists; Hypnotics and Sedatives; Ligands; Macaca mulatta; Midazolam; Pyridines; Pyrimidines; Receptors, GABA-A; Zolpidem | 2002 |
Zaleplon-induced coma and bluish-green urine: possible antidotal effect by flumazenil.
Topics: Acetamides; Aged; Antidotes; Color; Coma; Female; Flumazenil; Humans; Hypnotics and Sedatives; Male; Middle Aged; Pyrimidines; Suicide, Attempted; Treatment Outcome | 2002 |
[Poisonings with benzodiazepine-like drugs].
Topics: Acetamides; Antidotes; Azabicyclo Compounds; Flumazenil; Humans; Hypnotics and Sedatives; Norway; Piperazines; Poisoning; Pyridines; Pyrimidines; Zolpidem | 2003 |
Characterization of the interaction of indiplon, a novel pyrazolopyrimidine sedative-hypnotic, with the GABAA receptor.
Topics: Acetamides; Animals; Azides; Benzodiazepines; Binding Sites; Brain; Cell Membrane; Cerebellum; Cerebral Cortex; Chloride Channels; Flumazenil; GABA Modulators; gamma-Aminobutyric Acid; Kinetics; Male; Pyridines; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, GABA-A; Thiophenes; Triazolam; Tritium; Zolpidem | 2004 |
Flumazenil selectively prevents the increase in alpha(4)-subunit gene expression and an associated change in GABA(A) receptor function induced by ethanol withdrawal.
Topics: Acetamides; Alcohol-Induced Disorders, Nervous System; Animals; Animals, Newborn; Anticonvulsants; Cells, Cultured; Central Nervous System Depressants; Drug Interactions; Drug Tolerance; Ethanol; Flumazenil; GABA Modulators; gamma-Aminobutyric Acid; Gene Expression Regulation; Neuronal Plasticity; Patch-Clamp Techniques; Protein Subunits; Pyrimidines; Rats; Receptors, GABA-A; Substance Withdrawal Syndrome; Up-Regulation | 2007 |